Zhejiang Cancer Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

196

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

15 drugs in development

Approved1

Phase 31

Phase 213

Phase 13

Preclinical2

By Therapeutic Area

top 3

Oncology

1478%

Respiratory

16%

Infectious Disease

16%

R&D Momentum

74/100

Pipeline Velocity

39/100

Trial Completion Rate

92/100

Pipeline Concentration

62/100

Pipeline Freshness

46/100

Strategic Signals

↗Active in Respiratory but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Active, not recruiting

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Jul 10, 2026

Recruiting

A Phase Ib/II Study to Evaluate the Safety, Tolerability and Efficacy of IBI343 in Combination With Chemotherapy in Subjects With Advanced Pancreatic Cancer

Earlier

Jun 30, 2026TrialA Prognostic Research on First-Line Recurrent and Metastatic Cervical Cancer Using Circulating Cell-Free DNA and Human Papillomavirus Detection

Jun 27, 2026TrialA Clinical Translational Study Evaluating the Biodistribution, Radiation Dosimetry, and Safety of 68Ga-EV203 Injection in Patients With Hematological Malignancies

Jun 27, 2026TrialPhase II Study of AK112 Combined With Irinotecan Liposome in Patients With SCLC Who Progressed on Immune Checkpoint Inhibitors and Chemotherapy.

Jun 26, 2026TrialA Multi-center Observational Clinical Study Observing the Differences of Tongue Images Between Patients With Malignant Tumors and Healthy People

May 1, 2026TrialSacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases

Feb 10, 2026TrialThiotepa in Combination With Pirtobrutinib (a BTK Inhibitor) and Sintilimab (a PD-1 Inhibitor) for Frail or Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma

2 more events

Nov 24, 2025TrialA Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy

Nov 15, 2025TrialFirstline Sequential AG and mFOLFOX Combined With Serplulimab and Bevacizumab Versus AG Chemotherapy Alone in Advanced Pancreatic Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Infectious Disease(1 drug)

—

Infectious Disease(1 drug)

Oncology(14 drugs)

—

Oncology(14 drugs)

Respiratory(1 drug)

—

Respiratory(1 drug)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)